Literature DB >> 15242551

Oxidized phospholipids in oxidized low-density lipoprotein reduce the activity of tissue factor pathway inhibitor through association with its carboxy-terminal region.

Naoki Ohkura1, Sayuri Hiraishi, Hiroyuki Itabe, Tsutomu Hamuro, Yu-Ichi Kamikubo, Tatsuya Takano, Juzo Matsuda, Shuichi Horie.   

Abstract

Tissue factor pathway inhibitor (TFPI) is a Kunitz-type protease inhibitor that inhibits the initial reactions of blood coagulation. In this study, we explored the nature of active components that reduce the anticoagulant activity of TFPI in oxidized low-density lipoprotein (ox-LDL). The organic solvent-soluble fraction obtained from ox-LDL was fractionated by normal-phase HPLC. The binding profile of each fraction to TFPI showed a single peak eluting near purified oxidized phospholipid. To explore further the components in oxidized phospholipid that inhibit TFPI activity, we used oxidized phospholipids that mimic the biological activity of ox-LDL. The oxidation products of 1- and/or 2-oleoyl phosphatidylcholine or phosphatidylethanolamine were the most potent inhibitors of TFPI activity, whereas those of arachidonyl phosphatidylcholine possessed only a weak inhibitory effect on the TFPI activity. These oxidized phospholipids mainly associated with the C-terminal basic region of the TFPI molecule. The results indicate that oxidation products of delta-9 unsaturated phospholipids are candidate active components of ox-LDL that impair the function of TFPI through specific association with its C-terminal basic region.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15242551     DOI: 10.1089/1523086041361686

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  15 in total

Review 1.  Role of phospholipid oxidation products in atherosclerosis.

Authors:  Sangderk Lee; Konstantin G Birukov; Casey E Romanoski; James R Springstead; Aldons J Lusis; Judith A Berliner
Journal:  Circ Res       Date:  2012-08-31       Impact factor: 17.367

Review 2.  Interdependent biological systems, multi-functional molecules: the evolving role of tissue factor pathway inhibitor beyond anti-coagulation.

Authors:  Eric W Holroyd; Robert D Simari
Journal:  Thromb Res       Date:  2010-02-24       Impact factor: 3.944

3.  Differential regulation of endothelial cell permeability by high and low doses of oxidized 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphocholine.

Authors:  Vitaliy Starosta; Tinghuai Wu; Alejandro Zimman; Donald Pham; Xinyong Tian; Olga Oskolkova; Valery Bochkov; Judith A Berliner; Anna A Birukova; Konstantin G Birukov
Journal:  Am J Respir Cell Mol Biol       Date:  2011-10-13       Impact factor: 6.914

4.  Vascular-directed tissue factor pathway inhibitor overexpression regulates plasma cholesterol and reduces atherosclerotic plaque development.

Authors:  Shuchong Pan; Thomas A White; Tyra A Witt; Anca Chiriac; Cheri S Mueske; Robert D Simari
Journal:  Circ Res       Date:  2009-08-27       Impact factor: 17.367

Review 5.  Oxidative risk for atherothrombotic cardiovascular disease.

Authors:  Jane A Leopold; Joseph Loscalzo
Journal:  Free Radic Biol Med       Date:  2009-09-12       Impact factor: 7.376

Review 6.  Endothelial cell regulation by phospholipid oxidation products.

Authors:  Judith A Berliner; Nima M Gharavi
Journal:  Free Radic Biol Med       Date:  2008-04-20       Impact factor: 7.376

Review 7.  Generation and biological activities of oxidized phospholipids.

Authors:  Valery N Bochkov; Olga V Oskolkova; Konstantin G Birukov; Anna-Liisa Levonen; Christoph J Binder; Johannes Stöckl
Journal:  Antioxid Redox Signal       Date:  2010-04-15       Impact factor: 8.401

8.  Tissue factor pathway inhibitor prevents airway obstruction, respiratory failure and death due to sulfur mustard analog inhalation.

Authors:  Raymond C Rancourt; Livia A Veress; Aftab Ahmad; Tara B Hendry-Hofer; Jacqueline S Rioux; Rhonda B Garlick; Carl W White
Journal:  Toxicol Appl Pharmacol       Date:  2013-05-30       Impact factor: 4.219

9.  Endothelial-derived tissue factor pathway inhibitor regulates arterial thrombosis but is not required for development or hemostasis.

Authors:  Thomas A White; Tucker Johnson; Natalia Zarzhevsky; Cindy Tom; Sinny Delacroix; Eric W Holroyd; Susan A Maroney; Ripudamanjit Singh; Shuchong Pan; William P Fay; Jan van Deursen; Alan E Mast; Gurpreet S Sandhu; Robert D Simari
Journal:  Blood       Date:  2010-06-01       Impact factor: 22.113

Review 10.  Neutrophils and Platelets: Immune Soldiers Fighting Together in Stroke Pathophysiology.

Authors:  Junaid Ansari; Felicity N E Gavins
Journal:  Biomedicines       Date:  2021-12-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.